H. Cross John's most recent trade in Sonnet BioTherapeutics Holdings Inc was a trade of 1,452 Common Stock done . Disclosure was reported to the exchange on Dec. 11, 2023.
Stock | Client Name | Client Category | Action | Reported to Exchange | Quantity | Post Transaction Holding | Traded % | Avg. Price | Value | Security Type |
---|---|---|---|---|---|---|---|---|---|---|
Sonnet BioTherapeutics Hol... | H. Cross John | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 11 Dec 2023 | 1,452 | 1,588 | - | - | Common Stock | |
Sonnet BioTherapeutics Hol... | John H. Cross | Chief Financial Officer | Payment of exercise price or tax liability using portion of securities received from the company at price $ 1.06 per share. | 06 Feb 2023 | 1,960 | 23,927 | - | 1.1 | 2,078 | Common Stock |
Sonnet BioTherapeutics Hol... | John H. Cross | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 14 Dec 2022 | 15,519 | 160,684 | - | - | Common Stock | |
Sonnet BioTherapeutics Hol... | John H. Cross | Chief Financial Officer | Grant, award, or other acquisition of securities at price $ 0.00 per share. | 02 Jul 2020 | 78,214 | 78,214 | - | 0 | Common Stock |